Caption Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-20,000
Closed -$3.52M 1575
2025
Q4
$3.52M Sell
20,000
-75,000
-79% -$12.3M 0.02% 624
2025
Q3
$13.3M Buy
+95,000
New +$12.8M 0.1% 206
2024
Q1
Sell
-86,000
Closed -$22.3M 1217
2023
Q4
$22.3M Buy
86,000
+77,000
+856% +$18.9M 0.3% 72
2023
Q3
$2.31M Sell
9,000
-14,000
-61% -$3.74M 0.04% 537
2023
Q2
$6.55M Buy
+23,000
New +$6.85M 0.12% 228
2023
Q1
Sell
-206,800
Closed -$57.3M 1108
2022
Q4
$57.3M Sell
206,800
-197,400
-49% -$55.8M 0.89% 13
2022
Q3
$108M Buy
404,200
+363,000
+881% +$77.1M 1.49% 5
2022
Q2
$8.4M Sell
41,200
-10,000
-20% -$2.04M 0.12% 226
2022
Q1
$10.8M Sell
51,200
-126,100
-71% -$27.4M 0.13% 196
2021
Q4
$42.5M Sell
177,300
-33,600
-16% -$8.64M 0.48% 26
2021
Q3
$59.7M Buy
210,900
+21,800
+12% +$7.14M 0.68% 10
2021
Q2
$65.5M Sell
189,100
-111,900
-37% -$33.9M 0.85% 10
2021
Q1
$84.2M Buy
301,000
+88,600
+42% +$23.9M 1.81% 3
2020
Q4
$52M Buy
212,400
+182,400
+608% +$47.1M 1.19% 7
2020
Q3
$8.51M Sell
30,000
-20,000
-40% -$5.58M 0.2% 116
2020
Q2
$13.4M Buy
+50,000
New +$15M 0.45% 29
2019
Q1
Sell
-40,000
Closed -$12M 572
2018
Q4
$12M Buy
+40,000
New +$12.8M 0.96% 13

Other funds holding BIIB

Caption Management's BIIB Position: Q1 2026 in Review

Caption Management sold out of Biogen (BIIB) in Q1 2026, closing a stake of 53,000 shares — an estimated $9.77M sold.

Caption Management first reported a position in BIIB in Q4 2019 and held it in 15 quarters. The position peaked at $63.2M in Q3 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Caption Management reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 53,000 Biogen shares in Q1 2026, an estimated $9.77M.
  • Caption Management first reported a position in Biogen in Q4 2019 and held it in 15 quarters.
  • Caption Management's Biogen position peaked at $63.2M in Q3 2021.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.